The Longevity Industry Is Building Its Own Rules | Longevity News Roundup - Week 33, 2026

Sponsor: FlexBeam

FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.

Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.

Link: rechargehealthas.sjv.io/jRQyQ5

----------

In this week’s Longevity News Roundup, Phil Newman examines how longevity is developing the clinical standards, biological models and infrastructure needed to move from promising technology toward real-world medicine.

• Viome’s acquisition of Circulate Health brings therapeutic plasma exchange into a platform built around diagnostics, nutrition and coaching. Circulate’s network spans more than 200 partner clinics, creating a “measure, act, remeasure” model, while recent data on microplastics and biological age highlight the gap between measurable changes and proven healthspan outcomes.
• Longevity Clinics World and the Healthy Longevity Medicine Society have signed an MOU focused on evidence-based medicine, shared terminology, education, quality improvement and standardization. The collaboration also emphasizes that future accreditation must have separate governance and independent oversight.
• Kailera Therapeutics reported an active IND for ribupatide oral, with initiation of global Phase 3 obesity trials planned for the first half of 2027, and says its ribupatide injection Phase 2b high-dose obesity trial is fully enrolled with data anticipated in mid-2027; global Phase 3 KaiNETIC enrollment is on track for more than 4,700 participants with data expected in 2028.
• Immorta Bio proposes combining multi-omics, AI, digital twins and secure patient-owned data into a continuously learning precision-medicine system. Exploratory metabolomic data from more than 2,000 individuals identified nine metabolites associated with age.
• Insilico Medicine is developing its Virtual Aging Cell platform to model biological change across six interconnected scales, making biological age a core variable rather than simply an output. The key question is whether these simulations can generate predictions that survive experimental and clinical validation.

----------

News & References:

• Virtual cells learn to grow old → longevity.technology/news/virtual-cells-learn-to-grow-old/
• Immorta Bio maps out AI’s next move in longevity → longevity.technology/news/immorta-bio-maps-out-ais-next-move-in-longevity/
• Kailera Therapeutics reports Q2 2026 results, updates progress on obesity trials → longevity.technology/news/kailera-therapeutics-reports-q2-2026-results-updates-progress-on-obesity-trials/
• HLMS and Longevity Clinics World join forces on standards → longevity.technology/news/hlms-and-longevity-clinics-world-join-forces-on-standards/
• Is blood filtering the new wellness flex? → longevity.technology/news/is-blood-filtering-the-new-wellness-flex/

----------

Hosts:

Phil Newman: https://qrco.de/bgXpNY